With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.
With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.
Transcript
With the increased prevalence of real-world data in recent years, do you see a future where real-world data will replace clinical trials? Or will it be complementary to clinical trials and help fill in data gaps?
I think the short answer is complementary. I think it’s hard to imagine how a new agent, except for the situation where the tumor is uncommon, but for a general situation where the tumor is a common tumor and you’re trying to develop a new treatment, doing a randomized prospective trial, I think will still be the gold standard. Albeit, after that approval the opportunity to expand application, to find new patients that might have benefit—because one of the criticisms of randomized trials is that they’re very selective, very restrictive. In the real world, it’s just that. There are all kinds of patients with all types of comorbidities. Their blood count may not be the same, their chemistries, etc.
And there’s an opportunity to take a new agent and see how patients outside that clinical trial would do. And we actually did this in a situation with metastatic breast cancer where we took results from a clinical trial—it was a successful trial. We took that treatment that was successful and looked at our real-world data and the good news was that it wasn’t as restrictive as the clinical trial. We found similar benefits, so this was a confirmation. There were situations where the doctor will be asked by a patient, “Oh, it worked on a clinical trial, does it work in others?” And there is now the opportunity to say yes it worked in other people, not just patients on the clinical trial.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More